Limited guidance remains for the optimal management of tocilizumab-refractory CRS; some proposed treatments include drugs such as anakinra (IL-1 receptor antagonist), ruxolitinib (Janus kinase inhibitor), dasatinib (tyrosine kinase inhibitor), emapalumab (anti-IFN-γ), and siltuximab, as well as procedures such as hemofiltration, plasma exchange, and cytokine absorption. Here, IFNG is linked to congenital rubella syndrome.